VTVT vTv Therapeutics Inc.

1.32
+0.06  (+5%)
Previous Close 1.26
Open 1.26
Price To Book -1.47
Market Cap 73,033,585
Shares 55,345,245
Volume 213,173
Short Ratio
Av. Daily Volume 415,124

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 (Part 2) data due 1Q 2020.
TTP399
Type 1 Diabetes
Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints.
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 2/3 top-line data due 4Q 2020.
Azeliragon
Mild Alzheimer’s disease with type 2 diabetes

Latest News

  1. Largest Insider Trades of the Week
  2. vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences 
  3. vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
  4. vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
  5. vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
  6. vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
  7. Biotech entrepreneur seeks approval of 80-acre Triad R&D campus with 1,600 jobs
  8. Insiders Roundup: vTv Therapeutics, The Hershey
  9. VTv Therapeutics: 1Q Earnings Snapshot
  10. vTv Therapeutics Announces 2019 First Quarter Financial Results and Update
  11. Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
  12. Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E
  13. FDA Events Can Send Stocks Soaring: Here's One That No One Is Talking About
  14. vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
  15. Triad biopharmaceutical company seeks to raise $6 million
  16. vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
  17. vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
  18. Watch These 4 Healthcare Stocks Set the Pace on Friday (1/25/19)
  19. vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study